[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633557":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":30,"responsibleParty":50,"collaborators":11,"id":52,"slug":11,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Tang-Du Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Propranolol administered via intravenous pump for successive 7 days.","EXPERIMENTAL",null,[13],"Drug: Intravenous Pump-Delivered Propranolol",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Intravenous Pump-Delivered Propranolol","During the dose escalation phase, the proposed five dose levels of intravenous pump infusion of propranolol hydrochloride injection are as follows:\n\n* 0.01 mg\u002Fkg\u002Fh, administered as one group over 2 hours; repeated every 6 hours, with 3 groups per 24 hours, avoiding the period from 02:00 to 06:00 at night;\n\n  * 0.02 mg\u002Fkg\u002Fh, administered as one group over 2 hours; repeated every 6 hours, with 3 groups per 24 hours, avoiding the period from 02:00 to 06:00 at night;\n\n    * 0.03 mg\u002Fkg\u002Fh, administered as one group over 2 hours; repeated every 6 hours, with 3 groups per 24 hours, avoiding the period from 02:00 to 06:00 at night; ④ 0.04 mg\u002Fkg\u002Fh, administered as one group over 2 hours; repeated every 6 hours, with 3 groups per 24 hours, avoiding the period from 02:00 to 06:00 at night; ⑤ 0.05 mg\u002Fkg\u002Fh, administered as one group over 2 hours; repeated every 6 hours, with 3 groups per 24 hours, avoiding the period from 02:00 to 06:00 at night.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Yan Qu, M.D.","CONTACT","+86-18629074363","yanqu0123@icloud.com",{"name":27,"role":23,"phone":28,"phoneExt":11,"email":29},"Shunnan Ge, M.D.","+86-18165295569","gesn8561@163.com",[31],{"facility":32,"status":11,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Department of Neurosurgery , Tangdu Hospital, Fourth Military Medical University","Xi'an","Shaanxi","710038","China",{"type":38,"coordinates":39},"Point",[40,41],108.92861,34.25833,{"lat":41,"lon":40},[44,45,47],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"name":22,"role":46,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"name":48,"role":49,"phone":11,"phoneExt":11,"email":11},"Shunnnan Ge, M.D.","SUB_INVESTIGATOR",{"type":51,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100633557",false,"NCT07528235","An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH","An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing Stroke-Associated Pneumonia of Intravenous Pump-Delivered Propranolol in Patients With Intracerebral Hemorrhage","PROCHASE-DoE","Inclusion Criteria:\n\n* Patients aged \\> 18 and ≤ 80 years of age;\n* Can be treated with the study drug within 24 h of symptom onset;\n* No fever or infection was observed upon admission;\n* NIHSS score ≥10;\n* Supratentorial parenchymal haematoma (≥10 mL);\n* GCS score ≥ 6;\n* Patients or their family members sign informed consent forms.\n\nExclusion Criteria:\n\n* Infections within the last 4 weeks;\n* Use of antibiotics within the last 2 weeks;\n* Known pre-ICH dysphagia;\n* Secondary intracerebral hemorrhage or intraventricular hemorrhage resulting from trauma, vascular malformation, aneurysm, coagulopathy, anticoagulant drugs, thrombolysis, post-infarction hemorrhage transformation, hematopathy, moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, vasculitis, and other definite causes;\n* Previous disability with pre-ICH mRS score ≥ 2;\n* Brainstem hemorrhage;\n* Life expectancy less than 14 days;\n* Death appeared imminent;\n* Pregnancy or within 30 d of delivery;\n* Previous use (within 1 month) of β-blockers or reserpine;\n* Bronchial asthma or COPD;\n* Cardiogenic shock;\n* Degree II-III atrioventricular blocks;\n* Severe or acute heart failure;\n* Heart rate \\\u003C 65 beats\u002Fmin;\n* Known to be allergic to propranolol;\n* Severe liver or renal insufficiency;\n* History of malignant tumors;\n* Currently participating in other interventional clinical trials;\n* Currently, immunosuppressants and immunotherapies are being administered.","ALL","10 Years","80 Years",{"count":63,"type":64},30,"ESTIMATED","INTERVENTIONAL",[67],"PHASE1","This is an open-label, dose-escalation study on the safety, tolerability and preliminary efficacy for preventing stroke-associated pneumonia of propranolol in patients with intracerebral hemorrhage. Propranolol is administered via intravenous pump continuously for 7 days.",[70,71],"Intracerebral Hemorrhage","Stroke-Associated Pneumonia (SAP)",[73,70,74,75],"Propranolol","Stroke-Associated Pneumonia","Dose-Escalation Study","NOT_YET_RECRUITING","2026-04-07",{"date":79,"type":80},"2026-04-14","ACTUAL",{"date":82,"type":64},"2026-05-01",{"date":84,"type":64},"2026-11-01",{"name":5,"class":6},1]